Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Hepatocellular Carcinoma (HCC): early-phase trial registry
11 of 16 indexed Hepatocellular Carcinoma (HCC) trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #1,060 of 28,707 conditions by registered trial count.
16 US clinical trials · 11 currently recruiting · #1,060 of 28,707 conditions by registered trial count
Hepatocellular Carcinoma (HCC): 16 US clinical trials tracked, 11 recruiting.
Hepatocellular Carcinoma (HCC) is the subject of 16 registered US clinical trials on ClinicalTrials.gov, 11 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 9 in Phase 1-2 (earlier-stage). The most active sponsor is City of Hope Medical Center, running 2 of these trials.
Enrollment posture brief
Registry condition hepatocellular-carcinoma-hcc
OPEN 11 | RECR 69% | LATE 1 | EARLY 9 | RANK #1060 | SPON 2
Volume-matched condition peers
Nearest open-share peer: Deep Brain Stimulation (69% recruiting · 16 trials)
Hepatocellular Carcinoma (HCC) lists 11 open slots (69% of 16 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Hepatocellular Carcinoma (HCC) on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Hepatocellular Carcinoma (HCC) is recruiting above its size-band peers.
11 of 16 indexed trials (68.8%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
Sponsorship of Hepatocellular Carcinoma (HCC) trials is spread across many organizations.
City of Hope Medical Center accounts for 2 of 16 trials (12.5%). 15 distinct sponsors appear on at least one study for this condition label.
-
Typical Hepatocellular Carcinoma (HCC) enrolment sits around 171 participants.
Median target enrolment is 171 among the 16 trials that report a genuine target (sentinel values excluded). 6 of those (37.5%) plan for fewer than 100 participants.
-
Hepatocellular Carcinoma (HCC) splits between interventional and observational designs.
11 interventional and 5 observational studies make up this index (68.8% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
16 total, page 1 of 1
Study of Zanzalintinib in Combination With Immuno-Oncology Agents in Participants With Solid Tumors
Exelixis
NCT05176483
A Noninvasive and Screening miRNA Signature for Gastrointestinal Cancer
City of Hope Medical Center
NCT07224750
A Cell-free tsRNA Signature for Early Detection of Hepatocellular Carcinoma
City of Hope Medical Center
NCT07265271
The Dragon PLC Trial (DRAGON-PLC)
Maastricht University
NCT06914648
A Study to Evaluate the Safety and Therapeutic Activity of GI-102 As a Single Agent and in Combination with Conventional Anti-cancer Drugs, Pembrolizumab or Trastuzumab Deruxtecan(T-DXd) in Patients with Advanced Solid Tumors (KEYNOTE-G08)
GI Innovation
NCT05824975
Phase I Clinical Study To Evaluate Pharmacokinetic Profile, Safety, Efficacy and Immunogenicity Of Ipilimumab Biosimilar HLX13 Vs. YERVOY® (US-Sourced YERVOY®) As A First-Line Treatment For Patients With Unresectable Hepatocellular Carcinoma
Shanghai Henlius Biotech
NCT07176650
A Phase 1/1B Study of ST-01156, a Small Molecule RBM39 Degrader, in Patients With Advanced Solid Malignancies
SEED Therapeutics
NCT07197554
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
Bristol-Myers Squibb
NCT07291076
PSMA PET for the Staging and Management of Hepatocellular Carcinoma
VA Office of Research and Development
NCT07019844
ET140203 T Cells in Pediatric Subjects With Hepatoblastoma, HCN-NOS, or Hepatocellular Carcinoma
Eureka Therapeutics
NCT04634357
Liquid Biopsy for Hepatocellular Carcinoma Molecular Characterization After Y90
Palo Alto Veterans Institute for Research
NCT07303712
Multimodal Machine Learning Characterization of Solid Tumors
Ciprian Catana, MD, PhD
NCT04687969
A Study of Cobolimab Plus Dostarlimab in Pediatric and Young Adult Participants With Cancer
GlaxoSmithKline
NCT06521567
A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE
AstraZeneca
NCT06040099
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
BeiGene
NCT03412773
A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer or Other Select Solid Cancers
Bayer
NCT06345001
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 1 | 8 |
| Phase 2 | 1 |
| Phase 3 | 1 |
Top Sponsors
Named interventions
Most-linked intervention names on Hepatocellular Carcinoma (HCC) records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Hepatocellular Carcinoma (HCC) trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Hepatocellular Carcinoma (HCC) page
16 registered trials, 11 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 11 Hepatocellular Carcinoma (HCC) trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- City of Hope Medical Center sponsors the most Hepatocellular Carcinoma (HCC) trials on record, review their full trial history before evaluating a specific study. See City of Hope Medical Center's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Hepatocellular Carcinoma (HCC) condition card totals 16 registered trials; most-linked intervention Ipilimumab; top US site state California. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.